CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia

2018 ◽  
Vol 108 (1) ◽  
pp. 47-57
Author(s):  
Junichi Watanabe ◽  
Ken Sato ◽  
Yukiko Osawa ◽  
Toshikatsu Horiuchi ◽  
Shoichiro Kato ◽  
...  
Blood ◽  
2011 ◽  
Vol 118 (14) ◽  
pp. 3932-3941 ◽  
Author(s):  
Anna M. Jankowska ◽  
Hideki Makishima ◽  
Ramon V. Tiu ◽  
Hadrian Szpurka ◽  
Yun Huang ◽  
...  

Abstract Chronic myelomonocytic leukemia (CMML), a myelodysplastic/myeloproliferative neoplasm, is characterized by monocytic proliferation, dysplasia, and progression to acute myeloid leukemia. CMML has been associated with somatic mutations in diverse recently identified genes. We analyzed 72 well-characterized patients with CMML (N = 52) and CMML-derived acute myeloid leukemia (N = 20) for recurrent chromosomal abnormalities with the use of routine cytogenetics and single nucleotide polymorphism arrays along with comprehensive mutational screening. Cytogenetic aberrations were present in 46% of cases, whereas single nucleotide polymorphism array increased the diagnostic yield to 60%. At least 1 mutation was found in 86% of all cases; novel UTX, DNMT3A, and EZH2 mutations were found in 8%, 10%, and 5.5% of patients, respectively. TET2 mutations were present in 49%, ASXL1 in 43%, CBL in 14%, IDH1/2 in 4%, KRAS in 7%, NRAS in 4%, and JAK2 V617F in 1% of patients. Various mutant genotype combinations were observed, indicating molecular heterogeneity in CMML. Our results suggest that molecular defects affecting distinct pathways can lead to similar clinical phenotypes.


2019 ◽  
Vol 15 (1) ◽  
Author(s):  
Silvia Colussi ◽  
Rosanna Desiato ◽  
Chiara Beltramo ◽  
Simone Peletto ◽  
Paola Modesto ◽  
...  

2020 ◽  
Vol 50 (5) ◽  
pp. 879-884
Author(s):  
Anne Laure Roupie ◽  
Alexis Guedon ◽  
Benjamin Terrier ◽  
Constance Lahuna ◽  
Vincent Jachiet ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document